Maverick investor Cathie Wood has just done what she does best: stirring the stock market’s proverbial pot while maintaining her faith in innovation. ARK Invest’s Nov. 3 trade disclosure saw her shed $7.69 million worth of Palantir (PLTR), even after the defense AI poster-child posted superb Q3 earnings, sending its shares up 10% in five days. Year to date, Palantir stock has skyrocketed north of 170%, and it shot up 20% in the past month alone. At the same time, Wood doubled down on other conviction pl ...

Core Insights - Ten large-cap stocks were highlighted as top performers in the previous week, indicating strong market interest and potential investment opportunities [1] Group 1: Stock Performance - The article emphasizes the performance of large-cap stocks, suggesting they may be beneficial additions to investment portfolios [1]

Company Overview - Guardant Health, Inc. (GH) is a cancer genomics diagnostics company that utilizes the SMART platform for various cancer-related applications including screening, therapy selection, minimal residual disease (MRD), and surveillance across all cancer stages [1]. Business Segments - The company operates through several business segments, with Oncology being the primary focus, alongside Screening and Biopharma & Data [1].

Core Insights - Edwards Lifesciences has raised its 2025 sales outlook, driven by strong performance in its transcatheter heart-valve replacement (TAVR) business, which saw over 12% growth to $1.15 billion, surpassing expectations of $1.1 billion [1][2][5] Financial Performance - The company reported adjusted earnings of 67 cents per share on sales of $1.55 billion for Q3, with earnings rising 12% and sales climbing nearly 15%, both exceeding forecasts of 60 cents and $1.5 billion respectively [5][7] - Revenue from the nonsurgical replacement of mitral and tricuspid valves (TMTT) surged over 59% to $145.2 million, outperforming analyst projections of $142.1 million [6] Future Outlook - Edwards anticipates sales growth at the high end of the 9% to 10% range and projects adjusted profit of $2.56 to $2.62 per share, which is an increase of 9 cents from previous guidance [7] - Analysts expect earnings per share of $2.51 and total sales of $5.98 billion [7] Management Changes - The Chief Financial Officer, Scott Ullem, will transition from his role by mid-2026, prompting a selection process for a new CFO [8]

Group 1 - Narweena is an asset manager that focuses on identifying market dislocations caused by a poor understanding of long-term business prospects [1] - The firm aims to achieve excess risk-adjusted returns by targeting businesses with secular growth opportunities in markets with barriers to entry [1] - Narweena's investment strategy emphasizes company and industry fundamentals to uncover unique insights, with a high risk appetite and long-term investment horizon [1] Group 2 - The firm prefers smaller cap stocks and markets where competitive advantages are not immediately apparent [1] - Narweena believes that an aging population, low population growth, and stagnating productivity will create new investment opportunities distinct from historical trends [1] - Many industries may experience stagnation or secular decline, which could paradoxically enhance business performance due to reduced competition [1] Group 3 - Some businesses may face rising costs and diseconomies of scale, while economies are increasingly dominated by asset-light businesses [1] - The declining need for infrastructure investments is leading to a situation where a large pool of capital is pursuing a limited set of investment opportunities, driving up asset prices and compressing risk premia [1] - Richard Durant, the leader of Narweena, holds degrees in engineering and finance, as well as an MBA, and has passed the CFA exams [1]

Core Insights - Narweena is an asset manager that focuses on identifying market dislocations due to misunderstandings of long-term business prospects [1] - The firm aims to achieve excess risk-adjusted returns by targeting businesses with secular growth opportunities in markets with barriers to entry [1] - Narweena's investment strategy emphasizes company and industry fundamentals to uncover unique insights, with a preference for smaller cap stocks [1] Investment Philosophy - The company has a high risk appetite and a long-term investment horizon, seeking deeply undervalued stocks [1] - An aging population, low population growth, and stagnating productivity growth are expected to create new investment opportunities distinct from historical trends [1] - Industries facing stagnation or secular decline may see improved business performance due to reduced competition, while others may encounter rising costs and diseconomies of scale [1] Market Dynamics - The economy is increasingly influenced by asset-light businesses, leading to a declining need for infrastructure investments over time [1] - A large pool of capital is pursuing a limited set of investment opportunities, resulting in rising asset prices and compressed risk premia [1] Leadership Background - Richard Durant, the leader of Narweena, holds undergraduate degrees in engineering and finance from the University of Adelaide and an MBA from Nanyang Technological University [1] - Durant has passed the CFA exams, indicating a strong foundation in finance and investment analysis [1]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - Guardant Health Inc. shares increased over 25% to $90 in premarket trading following strong financial results for Q3 2025 and an upward revision of its full-year outlook [1][3][4] Financial Performance - For Q3 2025, revenue reached $265.2 million, marking a 39% increase from $191.5 million in Q3 2024, primarily due to a 40% year-over-year growth in Oncology test volume [3] - The non-GAAP net loss for Q3 2025 narrowed to $48.3 million or $0.39 per share, compared to a loss of $55.0 million or $0.45 per share in the same quarter last year [3] Future Outlook - The company now anticipates full-year 2025 revenue between $965 million and $970 million, an increase from the previous guidance of $915 million to $925 million [4] Product Offerings - Guardant Health provides several tests including the Guardant360 Liquid test, Guardant360 CDx test, Guardant Reveal blood test, and Guardant360 Response blood test, which are designed for various cancer diagnostics and monitoring [2] - The company also introduced Shield, a blood-based screening test for colorectal cancer, which is now available through a collaboration with Quest Diagnostics [5] Stock Performance - Over the past year, Guardant Health's stock has fluctuated between $21.85 and $73.31, closing at $72.27, up 3.87% prior to the recent surge [6]

Core Viewpoint - The article discusses the importance of enabling Javascript and cookies in browsers to ensure proper functionality and access to content [1] Group 1 - The article highlights that users may face access issues if they have an ad-blocker enabled [1] - It suggests disabling ad-blockers and refreshing the page to proceed [1]

Core Insights - Guardant Health reported a revenue of $265.2 million for the quarter ended September 2025, reflecting a year-over-year increase of 38.5% [1] - The earnings per share (EPS) was -$0.39, an improvement from -$0.45 in the same quarter last year, with an EPS surprise of +18.75% compared to the consensus estimate of -$0.48 [1] - The revenue exceeded the Zacks Consensus Estimate of $234.58 million by 13.05% [1] Financial Performance Metrics - Total oncology tests performed reached 74,000, surpassing the average estimate of 66,824 by three analysts [4] - Revenue from oncology was $184.4 million, exceeding the average estimate of $164.62 million from four analysts [4] - Revenue from biopharma and data was $54.73 million, compared to the average estimate of $48.38 million [4] - Revenue from screening was $24.11 million, significantly higher than the estimated $16.31 million [4] - Revenue from licensing and other sources was $1.95 million, slightly below the average estimate of $2.35 million [4] Stock Performance - Guardant Health's shares have returned +11.4% over the past month, outperforming the Zacks S&P 500 composite's +3.8% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]